 |
Fabian, M.A. et al. A small molecule-kinase
interaction map for clinical kinase inhibitors. Nat.
Biotechnol.
23, 329-336 (2005) |
|
Supplement to Fabian, M.A. et al. |
|
Carter, T.A. et al. Inhibition of drug-resistant
mutants of ABL, KIT, and EGF receptor kinases. Proc Natl
Acad Sci USA. 102, 11011-11016 (2005) |
| |
 |
Karaman, M.W. et
al. A quantitative analysis of kinase inhibitor
selectivity. Nat. Biotechnol. 26,
127-132 (2008) |
| |
|
|
Goldstein, D.M. et al. High-throughput kinase
profiling as a platform for drug discovery. Nat. Rev.
Drug Discovery. 7, 391-397 (2008) |
| |
|
Hill, R. J. et al. Pamapimod, a Novel p38 Mitogen-Activated
Protein Kinase Inhibitor: Preclinical Analysis of Efficacy
and Selectivity.J Pharmacol Exp Ther. 327, 610–619
(2008) |
| |
|
Rhodes, N. et al. Characterization of an Akt Kinase
Inhibitor with Potent Pharmacodynamic and Antitumor
Activity. Cancer Res. 7, 2366-2374 (2008) |
| |
|
Angell, R. et al. Biphenyl amide p38 kinase
inhibitors 3: Improvement of cellular and in vivo
activity. Bioorg. Med. Chem. Lett. 18, 4428–4432
(2008) |
| |
|
McDermott, U. et al. Genomic Alterations of Anaplastic
Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma
Kinase Inhibitors. Cancer Res 9, (2008) |
| |
|
Angell, R. et al.
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as
potent, selective, inhibitors of JNK2 and JNK3. Bioorg.
Med. Chem. Lett. 17, 1296–1301 (2007) |
| |
|
Angell, R. et al. Biphenyl amide p38 kinase
inhibitors 4: DFG-in and DFG-out binding modes. Bioorg.
Med. Chem. Lett. 18, 4433–4437 (2008) |
| |
|
Feng, Y. et al. Discovery of Substituted
4-(Pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as Potent
and Highly Selective Rho Kinase (ROCK-II) Inhibitors.J.
Med. Chem. 51, 6642–6645 (2008) |
| |
|
Goldstein, D. M. et al. Pathway to the Clinic:
Inhibition of P38 MAP Kinase. A Review of Ten Chemotypes
Selected for Development. Curr Top Med Chem. 5,
1017-1029 (2005) |
| |
